JPMorgan Is The Rally Over?
JPMorgan Chase (NYSE:JPM) share price is up 29% over the…
Sell
24
TTNP Quote, Financials, Valuation and Earnings
Last price:
$3.62
Seasonality move
:
102.66%
Day range:
$3.73 - $3.73
52-week range:
$3.03 - $14.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.40x
Volume:
434
Avg. volume:
24.9K
1-year change:
-47.46%
Market cap:
$3.4M
Revenue:
$1K
EPS (TTM):
-$5.21
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Titan Pharmaceuticals has 3653.35% upside to fair value with a price target of -- per share.
TTNP vs. S&P 500
-
Over the past 5 trading days, Titan Pharmaceuticals has overperformed the S&P 500 by 0.45% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Titan Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Titan Pharmaceuticals revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Titan Pharmaceuticals reported revenues of --.
Earnings Growth
-
Titan Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Titan Pharmaceuticals reported earnings per share of -$0.85.
Enterprise value:
580K
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $61K | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$10.2M | -$7.3M | -$4.6M | -$1.9M | -$666K | |
| EBITDA | -$10M | -$7.2M | -$4.6M | -$1.9M | -$666K | |
| Diluted EPS | -$15.39 | -$7.41 | -$5.21 | -$2.62 | -$0.85 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.3M | $7.2M | $3.6M | $8M | $2.9M | |
| Total Assets | $8.1M | $8M | $4.1M | $8.1M | $2.9M | |
| Current Liabilities | $4.2M | $2.7M | $2.6M | $1.4M | $483K | |
| Total Liabilities | $4.6M | $2.9M | $2.7M | $1.4M | $483K | |
| Total Equity | $3.5M | $5.1M | $1.4M | $6.6M | $2.4M | |
| Total Debt | $659K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8.2M | -$7.1M | -$3.9M | -$2.2M | -$506K | |
| Cash From Investing | -- | -- | -- | $504K | -- | |
| Cash From Financing | $5M | -- | -- | $406K | -$62K | |
| Free Cash Flow | -$8.2M | -$7.1M | -$3.9M | -$2.2M | -$506K | |
TTNP
Sector
Market Cap
$3.4M
$35M
Price % of 52-Week High
25.2%
42.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-47.47%
-41.61%
Beta (5-Year)
1.272
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.72
200-day SMA
Sell
Level
$4.45
Bollinger Bands (100)
Buy
Level
3.37 - 3.87
Chaikin Money Flow
Sell
Level
-1.2B
20-day SMA
Sell
Level
$3.77
Relative Strength Index (RSI14)
Buy
Level
50.05
ADX Line
Sell
Level
6.15
Williams %R
Neutral
Level
-62.5805
50-day SMA
Sell
Level
$3.75
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
1.3B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-67.1557)
Sell
CA Score
(Annual)
Level (-5.1377)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (9.0699)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Stock Forecast FAQ
In the current month, TTNP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TTNP average analyst price target in the past 3 months is --.
-
Where Will Titan Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Titan Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Titan Pharmaceuticals?
Analysts are divided on their view about Titan Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Titan Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Titan Pharmaceuticals's Price Target?
The price target for Titan Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TTNP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Titan Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of TTNP?
You can purchase shares of Titan Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Titan Pharmaceuticals shares.
-
What Is The Titan Pharmaceuticals Share Price Today?
Titan Pharmaceuticals was last trading at $3.62 per share. This represents the most recent stock quote for Titan Pharmaceuticals. Yesterday, Titan Pharmaceuticals closed at $3.73 per share.
-
How To Buy Titan Pharmaceuticals Stock Online?
In order to purchase Titan Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BlackRock a Buy, Sell or Hold
With a large suite of ETF offerings as well as…
Is Uber Stock a Buy, Sell or Hold?
Uber (NYSE:UBER) has been through quite a ride over the…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 18
UnitedHealth Group [UNH] is down 22.4% over the past day.
Sell
32
MAN alert for Apr 18
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 18
Global Payments [GPN] is down 17.44% over the past day.
